The pharmaceutical world is observing a remarkable shift in diabetes management with the emergence of GLP-1 transdermal devices. These patches offer a seemingly more convenient retatrutide peptide alternative to injections of GLP-1 medications, minimizing the frequency of daily needle sticks. The approach releases the compound directly through the